The blistering rally in Hims & Hers Health Inc. that’s captivated meme-stock traders has ground to a halt, setting up a ...

Compounding pharmacy and IBD 50 newcomer Hims & Hers Health is expected late Monday to report bullish earnings and sales ...

Hims & Hers Health Inc. (HIMS) stock tumbled over 25% on Friday, extending losses in after-hours trading after the U.S. Food ...

Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in ...

Hims & Hers Health (NYSE:HIMS) is set to report its earnings on Monday, Feb 24 after market close. HIMS stock plunged over 25 ...

Hims & Hers plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide. See ...

We will continue to offer access to personalized treatments as allowed by law to meet patient needs,” Hims & Hers CEO said.

The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

Semaglutide — the key ingredient in Ozempic and Wegovy — had been in shortage since 2022. Now that supply has stabilized, state-licensed compounding pharmacies and physicians must stop selling ...

The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...

Shares of Hims & Hers Health ( HIMS -25.79%) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost ...

The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...